ArticleAnnals of pediatric endocrinology & metabolism2025
The role of continuous glucose monitoring in improving glycemic control in adolescents with type 1 diabetes.
Article in Annals of pediatric endocrinology & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeContinuous glucose monitoring (CGM) technology offers real-time glucose feedback and has shown potential to improve glycemic control. This retrospective study evaluated the effect of CGM on glycemic outcomes in Korean children and adolescents with type 1 diabetes mellitus (T1DM) in a real-world setting.
methodsWe included 66 participants divided into a CGM group (n=22) and a self-monitoring blood glucose (SMBG) group (n=44). We compared changes in hemoglobin A1c (HbA1c) of the 2 groups over 1 year and observed changes in CGM activation time, mean glucose, glucose management indicator (GMI), coefficient of variation (CV), time in range (TIR), and hypoglycemia.
resultsThe CGM group had a mean age of 16.63 years and time from diagnosis to the initiation of study of 4.19 years, while those of the SMBG group were 17.85 years and 5.19 years, respectively. In the CGM group, mean HbA1c decreased from 8.68% at baseline to 7.92% at 12 months (P=0.011), whereas HbA1c increased from 8.46% to 8.93% in the SMBG group (P<0.001). The changes in HbA1c at 1 year between the CGM and SMBG groups were significantly different (-0.76%±1.39% vs. 0.47%±1.38%, P=0.001). CGM activation time decreased slightly (89.09% to 79.24%, P=0.093), and there were no significant changes in TIR, mean glucose, GMI, CV, or hypoglycemia over time.
conclusionCGM use in Korean children and adolescents with T1DM significantly improves HbA1c levels over 12 months compared to SMBG. The implementation of CGM may provide valuable benefits in glycemic control and potentially reduce the risk of diabetes-related complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.